Lynn Seely - 09 Feb 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: President and CEO, Director
Issuer ticker: LYEL
Reported as of: 09 Feb 2026
Net transaction value: -$10,127
SEC form: 4
Accepted by SEC: 11 Feb 2026, 21:03:03 UTC
Prior SEC filing: 12 Nov 2025
Next SEC filing: 12 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Meltz, Attorney-in-Fact

Key filing fact

Lynn Seely filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 11 Feb 2026.

Key facts

This page summarizes Lynn Seely's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2026, 21:03.

Change

Previous filing in this sequence was filed on 12 Nov 2025.
Current net transaction value: -$10,127.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001327111 Primary reporting owner

Seely Lynn

Relationship: President and CEO, Director
Address: C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO
Signature: /s/ Mark Meltz, Attorney-in-Fact
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LYEL transaction

Common Stock

Award

Transaction value: $0
Shares: +20,000
Change %: +32%
Price: $0.000000
Shares after: 82,159
Date: 09 Feb 2026
Ownership: Direct
Footnotes: F1

LYEL transaction

Common Stock

Sale

Transaction value: $10,127
Shares: -438
Change %: -0.53%
Price: $23.12
Shares after: 81,721
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +155,000
Change %
Price: $0.000000
Shares after: 155,000
Date: 10 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 155,000
Exercise price: $23.71
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date.

Footnote F2

Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

Footnote F3

Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.